Followers | 29 |
Posts | 2243 |
Boards Moderated | 0 |
Alias Born | 12/25/2016 |
Saturday, August 12, 2017 9:40:38 AM
ACCESSWIRE - Thu Aug 3, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Marinus Pharmaceuticals may have reported a loss in its second quarter, but traders may have been encouraged by the company's business update about a phase 2 Magnolia study.
Marinus Pharmaceuticals, Inc.'s shares closed up 2.73% yesterday on trading volume higher than the average trading volume. Share price rose despite the company reporting a loss in its second quarter report of $4.6 million and a loss of 21 cents per share. The biotech company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, also announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of CDKL5 disorder. CEO Christopher M. Cashman commented, "This quarter Marinus significantly advanced the development of ganaxolone, which positions us to achieve several value-creating milestones in the second half of this year. With intravenous dosing occurring in our Magnolia study and plans to initiate the Amaryllis study with ganaxolone capsules, we are well positioned to evaluate inpatient and outpatient treatments with ganaxolone in women diagnosed with both severe and moderate PPD."
Recent MRNS News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:15:20 PM
- Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day • Business Wire • 09/20/2024 12:00:00 PM
- Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 • Business Wire • 09/12/2024 12:00:00 PM
- Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 12:00:00 PM
- Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 • Business Wire • 08/19/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:09:04 AM
- Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results • Business Wire • 08/13/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:06 PM
- Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS • PR Newswire (US) • 08/05/2024 09:45:00 AM
- Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 • Business Wire • 07/30/2024 12:00:00 PM
- The Gross Law Firm Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS • PR Newswire (US) • 07/25/2024 09:45:00 AM
- Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder • Business Wire • 07/18/2024 11:00:00 AM
- Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNS • PR Newswire (US) • 07/12/2024 09:45:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/08/2024 08:32:41 PM
- The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 11:01:43 AM
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus • Business Wire • 06/17/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/06/2024 08:55:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:11 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM